NativeMed: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of NativeMed’s website, https://www.nativemed.net, FDA Establishment Identifier (FEI) 3044024130, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “The compounded tirzepatide products displayed on your website feature NativeMed’s logo on the pictured label, suggesting NativeMed is the compounder of those drugs when in fact it is not.”

2. 2

   ““The same active ingredient in Ozempic® and Wegovy®””

3. 3

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

nativemed.net returned a live storefront when we checked in August 2026, running a seasonal promotion and showing semaglutide and tirzepatide as in stock. We did not review every page on the site.

This letter is a small but clarifying variation. A brand mark is not a word, and you might assume the rule about names on drug labels turns on printed text — FDA's wording here says otherwise, treating a logo as making the same representation. The underlying idea is consistent across every private-label letter in this dataset: whatever a vial's packaging says about who made it is a claim, and if the company on the front did not compound the contents, the impression is misleading. What follows for a shopper is worth carrying to every listing you compare. Branded packaging is a design decision made by the seller, so two vials with different logos on them can come from the same pharmacy, and two vials with the same price can come from different ones. If you want to know what you are buying, the question is which facility filled it, and that is exactly what FDA asked this company to disclose.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence NativeMed failed to respond.